Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3664 |
THZ1
CDK7 inhibitor,THZ1 2HCl |
CDK | Cell Cycle/Checkpoint |
THZ1 (CDK7 inhibitor) 是一种新型的选择性强效共价 CDK7 抑制剂。它还抑制CDK12和CDK13,并下调 MYC 表达。 | |||
T7296 |
THZ2
CDK7-IN-1 |
CDK | Cell Cycle/Checkpoint |
THZ2 (CDK7-IN-1) 是 THZ1 的类似物,是一种有效的选择性 CDK7 抑制剂 ,IC50值为 13.9 nM。它有治疗三阴性乳腺癌的潜力。 | |||
T22461 |
YKL-5-124
|
CDK | Cell Cycle/Checkpoint |
YKL-5-124 是选择性不可逆CDK7共价抑制剂,对CDK7和CDK7/Mat1/CycH 的IC50分别为 53.5 nM 和 9.7 nM。它诱导强烈的细胞周期停滞,并抑制 E2F 驱动的基因表达。它对 CDK7 的生化和细胞选择性优于 CDK12/13。它对CDK7的选择性比 CDK9 和 CDK2 高 100 倍以上。 | |||
T13044 |
Mevociclib
SY-1365 |
CDK | Cell Cycle/Checkpoint |
Mevociclib (SY-1365) 是一种高效选择性 CDK7抑制剂,Ki 值为 17.4 nM。它具有抗血液肿瘤和侵袭性实体肿瘤作用,有抗增殖和凋亡活性。 | |||
T10898 |
Samuraciclib hydrochloride
ICEC0942 hydrochloride,CT7001 hydrochloride |
Apoptosis; CDK | Apoptosis; Cell Cycle/Checkpoint |
Samuraciclib hydrochloride (ICEC0942 hydrochloride) 是一种具有选择性,ATP 竞争性和口服活性的CDK7抑制剂,IC50为 41 nM。它以 GI50值为 0.2-0.3 µM 来抑制乳腺癌细胞系的生长,具有抗肿瘤作用。 | |||
T22440 |
TP-353
EOS-61973 |
CDK | Cell Cycle/Checkpoint |
TP-353 (EOS-61973) 是一种 CDK7 抑制剂。 | |||
T4051 |
LDC4297
LDC044297 |
CDK; HSV | Cell Cycle/Checkpoint; Microbiology/Virology |
LDC4297 (LDC044297)是 CDK7的一种高效选择性抑制剂,IC50值为0.13 nM。 | |||
T6162 |
BS-181 hydrochloride
BS-181 HCl |
CDK | Cell Cycle/Checkpoint |
BS-181 hydrochloride (BS-181 HCl) 是一种高度选择性的CDK7抑制剂,IC50值为 21 nM。它对 CDK7 的选择性是对 CDK1、2、4、5、6 和 9 的 40 倍以上。 | |||
T4417 |
LDC-4297 HCl (1453834-21-3(free base))
|
CDK | Cell Cycle/Checkpoint |
LDC-4297 HCl (1453834-21-3(free base)) 是一种有效的选择性 CDK7 抑制剂,IC50 为 0.13 nM。 | |||
TQ0060 |
LY2857785
|
Apoptosis; CDK | Apoptosis; Cell Cycle/Checkpoint |
LY2857785 是 I 型可逆的 ATP 竞争性 CDK9、CDK8和 CDK7抑制剂,IC50分别为 11 nM、16 nM 和 246 nM。 | |||
T35332 |
THZ1 2HCl
THZ1二盐酸盐,THZ1 2HCl,THZ1 Dihydrochloride |
CDK | Cell Cycle/Checkpoint |
THZ1 2HCl (THZ1 Dihydrochloride) 是一种选择性、共价和变构的 CDK7 抑制剂,IC50 为 3.2 nM。 THZ1 2HCl 对多种癌细胞系具有抗增殖作用。 | |||
T36038 |
SY-5609
CDK7-IN-3 |
CDK | Cell Cycle/Checkpoint |
SY-5609 是一种选择性的非共价 CDK7 抑制剂(KD = 0.065 nM),具有抗肿瘤活性并抑制细胞凋亡。 | |||
T16784 |
Roniciclib
BAY 1000394 |
CDK | Cell Cycle/Checkpoint |
Roniciclib (BAY 1000394) 是一种有效的泛 CDK 抑制剂和新型口服细胞毒剂,对 CDK1、CDK2、CDK3、CDK4、CDK7 和 CDK9 的 IC50值为 5-25 nM。 | |||
T39752 |
CDK12-IN-2
CDK12 inhibitor 2,CDK12-IN-2 |
CDK | Cell Cycle/Checkpoint |
CDK12-IN-2 (CDK12 inhibitor 2) 是一种有效的选择性 CDK12 抑制剂,对 CDK12、CDK2、CDK7 和 CDK9 的 IC50 为 52 nM、>100 μM、>10 μM 和 16 μM。 CDK12-IN-2可用于研究CDK12的功能。 | |||
T2095 |
Seliciclib
Roscovitine,R-roscovitine,CYC202 |
CDK | Cell Cycle/Checkpoint |
Seliciclib (Roscovitine) 是 Cdk2/cyclin E 的有效抑制剂,IC50为0.1 µM。它还抑制 Cdk7/cyclin H、Cdk5/p35 和 Cdc2/cyclin B,IC50为 0.49、0.16和0.65 µM。 | |||
T6205 |
AT7519
|
Apoptosis; GSK-3; CDK | Apoptosis; Cell Cycle/Checkpoint; PI3K/Akt/mTOR signaling; Stem Cells |
AT7519 是一种CDK 抑制剂,对 CDK1,CDK2,CDK4-CDK6 以及 CDK9 的IC50值分别为 210,47,100,13,170 和 <10 nM。 | |||
T6049 |
SNS-032
SNS032,BMS-387032 |
Apoptosis; GSK-3; CDK | Apoptosis; Cell Cycle/Checkpoint; PI3K/Akt/mTOR signaling; Stem Cells |
SNS-032 (BMS-387032) 是选择性的CDK2/7/9有效抑制剂,IC50值分别为 48 nM/62 nM/4 nM。它有抗肿瘤作用。 | |||
T6312 |
R547
Ro 4584820 |
Apoptosis; GSK-3; PKA; CDK | Apoptosis; Cell Cycle/Checkpoint; PI3K/Akt/mTOR signaling; Stem Cells; Tyrosine Kinase/Adaptors |
R547 (Ro 4584820) 是一种口服有效,选择性, ATP 竞争性CDK 抑制剂,对 CDK1/cyclin B、 CDK2/cyclin E 和 CDK4/cyclin D1 作用的Ki 值分别为 2 nM、3 nM、1 nM。 | |||
T2378 |
RGB-286638 free base
|
GSK-3; MEK; JAK; CDK | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; MAPK; PI3K/Akt/mTOR signaling; Stem Cells |
RGB-286638 free base 是一种新型 CDK 抑制剂,抑制cyclin T1-CDK9、cyclin B1-CDK1、cyclin E-CDK2、cyclin D1-CDK4、cyclin E-CDK3和p35-CDK5活性,IC50分别为 1、2、3、4、5 和 5 nM。它也抑制 GSK-3β、TAK1、Jak2 和 MEK1,IC50值分别为 3、5、50和 54 nM。 | |||
T14943 |
CGP60474
|
VEGFR; CDK; PKC | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
CGP60474 是一种高效的抗内毒素药物,抑制细胞周期蛋白依赖激酶(CDK) ,抑制 CDK1/B、CDK2/E、CDK2/a、CDK4/D、CDK5/p25、CDK7/H 和 CDK9/T 的IC50分别为 26、3、4、216、10、200 和 13 nM。它是选择性和 ATP 竞争性PKC 抑制剂。 | |||
T27805 |
LDC3140
LDC 3140,LDC-3140,LDC043140 |
||
LDC3140 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7). | |||
T79169 | CDK7-IN-22 | CDK | Cell Cycle/Checkpoint |
CDK7-IN-22 (compound 101)为CDK7选择性抑制剂,具备抗肿瘤活性。 | |||
T39247 |
CDK7-IN-5
CDK7-IN-5 |
||
CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104). | |||
T75121 | CDK7-IN-21 | ||
CDK7-IN-21 (compound A22) 是一种有效的 CDK7抑制剂。 | |||
T62926 |
CDK7/12-IN-1
|
||
CDK7/12-IN-1 是一种 CDK7/12 的选择性抑制剂,作用于 CDK7 (IC50: 3 nM) 和 CDK 12 (IC50: 277 nM)。抑制 CDK7 和 CDK12 是一种有效抑制肿瘤生长的有效。 | |||
T62759 |
CDK7-IN-13
|
||
CDK7-IN-13 是一种嘧啶基衍生化合物,是一种 CDK7 的有效抑制剂。CDK7-IN-13 具有潜力进行多种癌症的研究(尤其是转录失调的癌症)。 | |||
T39943 |
CDK7-IN-6
CDK7-IN-6 |
||
CDK7-IN-6 is a highly effective and specific inhibitor (IC50 ≤100 nM) of cyclin-dependent kinase 7 (CDK7). It showcases remarkable selectivity, with more than a 200-fold preference for CDK7 over CDK1, CDK2, and CDK5. This compound holds significant potential for cancer research purposes. | |||
T24643 |
YKL-1-116
YKL 1 116,YKL1116 |
||
YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor. | |||
T63381 |
CDK7-IN-8
|
||
CDK7-IN-8 是 CDK7 的有效抑制剂 (IC50: 54.29 nM),对一些癌细胞和体内肿瘤模型表现出抑制活性。 | |||
T40264 |
CDK7-IN-7
CDK7-IN-7 |
||
CDK7-IN-7, a highly potent and selective inhibitor of CDK7 kinase, exhibits remarkable activity with an IC50 of less than 50 nM. | |||
T62791 | CDK7-IN-16 | ||
CDK7-IN-16 (compound 9) 是一种 CDK 7 的有效抑制剂 (IC50: 1-10 nM)。CDK7-IN-16 能够用于研究抗癌,特别是转录异常的癌症。 | |||
T39372 |
CDK7-IN-1
CDK7-IN-1 |
||
CDK7-IN-1 is an analog derived from YKL-5-124 and functions as an inhibitor of cyclin-dependent kinase 7 (cdk7). It exhibits strong inhibitory activity, with an IC50 value of less than 100 nM (WO 2016105528 A2, Compound 215). | |||
T63217 |
CDK7-IN-15
|
||
CDK7-IN-15 是嘧啶基衍生化合物,也是 CDK7 的有效抑制剂。CDK7-IN-15 对多种癌症具有研究潜力,尤其是转录失调的癌症。 | |||
T61922 |
CDK7-IN-12
|
||
CDK7-IN-12 是有效的CDK7抑制剂,在调控转录和细胞周期中起关键作用。CDK7-IN-12可以有效抑制体外和体内恶性肿瘤的增殖。CDK7-IN-12 在癌症疾病中具有研究潜力。 | |||
T63301 |
CDK7-IN-18
|
||
CDK7-IN-18 是嘧啶基衍生化合物,是 CDK7 的有效抑制剂。CDK7-IN-18 表现出多种癌症的研究潜力,尤其是转录失调的癌症。 | |||
T23458 |
THZ1 Hydrochloride (1604810-83-4 free base)
THZ1 Hydrochloride |
Others | Others |
THZ1 is a covalent inhibitor of CDK7 (IC50: 3.2nM). | |||
T40353 |
CDK7/9-IN-1
CDK7/9-IN-1 |
||
CDK7/9-IN-1 is a specific inhibitor of cyclin-dependent kinases 7/9 (CDK7/9). It specifically targets CDK7, while also displaying inhibitory activity against CDK9. CDK7/9-IN-1 demonstrates excellent inhibitory potency against CDK7, with IC50 values of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. Furthermore, CDK7/9-IN-1 inhibits CDK9 with an IC50 of 2.14 μM after 3 hours pre-incubation. Its application in cancer research makes it valuable for su... | |||
T63108 |
CDK7-IN-14
|
||
CDK7-IN-14 是一种嘧啶基衍生化合物,是一种 CDK7 的有效抑制剂。CDK7-IN-14 具有潜力进行多种癌症(尤其是转录失调的癌症)的研究。 | |||
T79881 |
CDK7-IN-25
|
CDK | Cell Cycle/Checkpoint |
CDK7-IN-25 (CY-16-1)为一CDK-7抑制剂,具有极低的半抑制浓度(IC50<1nM),主要用于癌症研究领域。 | |||
T71197 | JW-7-25-1 | ||
JW-7-25-1 is a potent multi-target inhibitor, acting on MELK, PIK3CA, mTOR, GSK3A and CDK7. | |||
T73633 | YKL-5-124 TFA | ||
YKL-5-124 TFA是一种高效、选择性不可逆的CDK7共价抑制剂,具有53.5 nM对CDK7的IC50值和9.7 nM对CDK7/Mat1/CycH的IC50值。此化合物对CDK7的选择性超过CDK9和CDK2 100倍以上,对CDK12和CDK13则无活性。YKL-5-124 TFA能显著诱导细胞周期停滞,抑制E2F驱动的基因表达,对RNA聚合酶II的磷酸化状态影响微乎其微。 | |||
T39864 |
CDK7-IN-2 hydrochloride hydrate
CDK7-IN-2 hydrochloride hydrate |
||
CDK7-IN-2 hydrochloride hydrate (Example 6) is a highly effective and specific inhibitor of the CDK7 enzyme. This compound exhibits significant anti-cancer properties. | |||
T63724 | CDK7-IN-10 | ||
CDK7-IN-10 是 CDK7 抑制剂 (IC50<100 nM)。CDK7-IN-10 能够抑制激酶的活性,具有抑制细胞生长及诱导细胞凋亡的潜力。 | |||
T13367 |
YKL-5-124 TFA (1957203-01-8 free base)
YKL-5-124 TFA |
Others | Others |
YKL-5-124 TFA is a potent, selective, irreversible and covalent inhibitor of CDK7 (IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively). | |||
T63410 |
CDK7-IN-17
|
||
CDK7-IN-17 是嘧啶基衍生化合物,也是 CDK7 的有效抑制剂。CDK7-IN-17 对多种癌症,尤其是转录失调的癌症表现出研究潜力。 | |||
T79604 |
SHR5428
|
CDK | Cell Cycle/Checkpoint |
SHR5428为口服选择性非共价CDK7抑制剂,显示出高效CDK7酶活性抑制(IC50=2.3 nM)。它还有效抑制MDA-MB-468细胞系中的三阴性乳腺癌细胞活性(IC50=6.6 nM)。 | |||
T1947 |
BS-181
BS 181 |
Apoptosis; CDK | Apoptosis; Cell Cycle/Checkpoint |
BS-181 是一种高度选择性的 CDK7 抑制剂,IC50为21 nM。它抑制CDK2、CDK5 和 CDK9 的IC50值分别为 880 nM、3000 nM 和 4200 nM 。它诱导细胞凋亡,有癌症研究相关的研究潜力。 | |||
T10546 |
bio-THZ1
|
CDK | Cell Cycle/Checkpoint |
bio-THZ1 is a biotinylated version of THZ1. THZ1 is a selective and irreversibly covalent CDK7 inhibitor (IC50: 3.2 nM). | |||
T14915 |
CDK12-IN-E9
|
CDK | Cell Cycle/Checkpoint |
CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux. It has a weak binding ability to CDK7/CyclinH complex (IC50> 1 μM). | |||
T82227 |
HDAC1/CDK7-IN-1
|
HDAC | Chromatin/Epigenetic; DNA Damage/DNA Repair |
HDAC1/CDK7-IN-1(compound 8e)是一款针对CDK7和HDAC1的双重抑制剂,其IC50值分别为893 nM 和248 nM 。该化合物能有效抑制MDA-MB-231、MCF-7、A549及HCT-116等多种癌细胞系的生长。此外,HDAC1/CDK7-IN-1在HCT-116细胞中诱发了细胞周期阻滞与凋亡(apoptosis)现象,并能够抑制其细胞迁移能力。 |